MedTrace Logo

Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

NCT03321747 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-07-26

No results posted yet for this study

Summary

The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung. While three fraction SABR is effective for the treatment of early stage non small cell lung carcinoma (NSCLC) of all histologies, it is not safe for many patients. While four and five fraction SABR is safe, recently published data and our institutional data suggests that local control for early stage squamous cell carcinoma of the lung using the current four or five fraction SABR is suboptimal.

Conditions

Interventions

RADIATION

Stereotactic Ablative Body Radiation (SABR)

Treatments shall not be delivered more frequently than every other day.

Sponsors & Collaborators

  • Indiana University School of Medicine

    collaborator OTHER

  • Indiana University

    lead OTHER

Principal Investigators

  • Tim Lautenschlaeger, MD · Indiana University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-20
Primary Completion
2020-07-09
Completion
2020-07-09
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03321747 on ClinicalTrials.gov